Overview
Description
Alzamend Neuro Inc. is a biopharmaceutical company focused on the development of novel products for the treatment of neurodegenerative diseases and psychiatric conditions. The company's primary objective is to advance therapeutics that address Alzheimer's disease, a debilitating and increasingly prevalent neurological disorder, as well as other neurodegenerative conditions that affect cognitive function and quality of life. Alzamend’s portfolio includes the development of patented compounds aimed at slowing the progression of such diseases, reflecting a commitment to innovation in the pharmaceutical sector.
Founded with a mission to tackle unmet medical needs, Alzamend Neuro operates at the intersection of healthcare science and technology. It seeks to transform the standard of care in neurology through strategic research and clinical trials. The company plays a significant role in the medical and biotechnology sectors, contributing to efforts that may offer novel solutions to some of today's most challenging psychiatric and cognitive health issues. Based in the United States, Alzamend Neuro continues to advance its research initiatives, impacting both the local and broader global communities within the healthcare and pharmaceutical markets.
About
CEO
Mr. Stephan Jackman
Employees
4
Address
3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, 30326, GA
United States
Second Floor, Suite 103
Atlanta, 30326, GA
United States
Phone
844 722 6333
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNCM